Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04627571 · ClinicalTrials.gov registry record
Corneal Nerves After Treatment With Cenegermin
A clinical trial of Neurotrophic Keratitis, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- 8
- Enrollment target
- 1
- Study location
NCT04627571 is a study of Neurotrophic Keratitis that has completed, run by University of California, Los Angeles. The registered enrollment target is 8 participants, below the 23-participant average among 6 other Neurotrophic Keratitis trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04627571, a study of Neurotrophic Keratitis, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Neurotrophic keratopathy (NK) is a condition in which patients have fewer or complete absence of nerves in the cornea, characterized by the reduced or absent corneal sensation. The lack of nerves in the cornea also result in damages of the cornea and in severe situation the loss of the eye. Cenegermin (trade name Oxervate) is a nerve growth factor eye drops designed to treat NK, and currently, it is the only FDA-approved medication for this purpose. Even though cenegermin is effective in the majority of patients, there is a lack of understanding of how cenegermin works in the eye. In this study, investigators aim to determine the structural and functional effects of cenegermin on the cornea, using non-invasive technologies including in vivo confocal microscopy on study participants with NK over the course of a year.
Conditions Studied
Interventions
- DRUG Cenegermin Ophthalmic Solution [Oxervate]
Study Locations (1)
California
- University of California, Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-05-23 |
| Est. Completion | 2025-03-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04627571
The ClinicalTrials.gov registry entry for NCT04627571 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 23-participant average among 6 other Neurotrophic Keratitis trials with a reported enrollment target (65% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neurotrophic Keratitis appearing as the primary indexed condition, and to 1 intervention - of which Cenegermin Ophthalmic Solution [Oxervate] is the first listed.
NCT04627571 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04627571 about?
NCT04627571 is a clinical study titled "Corneal Nerves After Treatment With Cenegermin". Neurotrophic keratopathy (NK) is a condition in which patients have fewer or complete absence of nerves in the cornea, characterized by the reduced or absent corneal sensation. The lack of nerves in the cornea also result in damages of the cornea and in severe situation the loss of the eye. Ceneger...
What is the current status of trial NCT04627571?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2022-05-23. Estimated completion is 2025-03-25.
What conditions does trial NCT04627571 study?
This clinical trial studies the following conditions: Neurotrophic Keratitis.
What interventions are being tested in trial NCT04627571?
The interventions under investigation include: Cenegermin Ophthalmic Solution [Oxervate] (DRUG).
Who is sponsoring clinical trial NCT04627571?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04627571 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurotrophic Keratitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis
RECRUITING · Phase 1
-
Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis
RECRUITING · Phase 2
-
OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate
RECRUITING
-
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
RECRUITING · Phase 4
-
DOMPE -MT Neurotrophic Keratitis
ACTIVE NOT RECRUITING · Phase 4
-
DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.